Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Shukla

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Neurology India|February 3, 2007
Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing countryM V Padma, M B Singh, R Bhatia, et al.
Ophthalmology. Glaucoma|November 14, 2025
Perimetry Testing in the 10th Decade of LifeAri Leshno, Charu Vyas, Emmanouil Tsamis, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2017
Cannabinoid CB<sub>1</sub> Discrimination: Effects of Endocannabinoids and Catabolic Enzyme InhibitorsMichael Z Leonard, Shakiru O Alapafuja, Lipin Ji, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 22, 2021
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomesEric J Shiuey, Nikki A Mehran, Melih Ustaoglu, et al.
Journal of Current Glaucoma Practice|July 24, 2023
Evaluation of the Hypertensive Phase after Ahmed Glaucoma Valve Implantation in Neovascular GlaucomaSunidhi Ramesh, Wesam S Shalaby, Jonathan S Myers, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 5, 2013
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonistsBrian D Kangas, Marcus S Delatte, V Kiran Vemuri, et al.
Journal of Medicinal Chemistry|October 8, 2010
Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonistSpyros P Nikas, Shakiru O Alapafuja, Ioannis Papanastasiou, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 18, 2005
Unidirectional whole body turning: a new lateralising sign in complex partial seizuresG Shukla, M Bhatia, M V Padma Srivastava, et al.
Journal of Ophthalmology|February 2, 2024
Long-Term Surgical Outcomes of Glaucoma Drainage Implants in Eyes with Preoperative Intraocular Pressure Less than 19 mmHgShahin Hallaj, Jae-Chiang Wong, Lauren E Hock, et al.
The Review of Scientific Instruments|July 10, 2021
Observations of visible argon line emissions and its spatial profile from Aditya-U tokamak plasmaK Shah, J Ghosh, G Shukla, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Neurology India|February 3, 2007
Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing countryM V Padma, M B Singh, R Bhatia, et al.
Ophthalmology. Glaucoma|November 14, 2025
Perimetry Testing in the 10th Decade of LifeAri Leshno, Charu Vyas, Emmanouil Tsamis, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 27, 2017
Cannabinoid CB<sub>1</sub> Discrimination: Effects of Endocannabinoids and Catabolic Enzyme InhibitorsMichael Z Leonard, Shakiru O Alapafuja, Lipin Ji, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|September 22, 2021
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomesEric J Shiuey, Nikki A Mehran, Melih Ustaoglu, et al.
Journal of Current Glaucoma Practice|July 24, 2023
Evaluation of the Hypertensive Phase after Ahmed Glaucoma Valve Implantation in Neovascular GlaucomaSunidhi Ramesh, Wesam S Shalaby, Jonathan S Myers, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 5, 2013
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonistsBrian D Kangas, Marcus S Delatte, V Kiran Vemuri, et al.
Journal of Medicinal Chemistry|October 8, 2010
Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonistSpyros P Nikas, Shakiru O Alapafuja, Ioannis Papanastasiou, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 18, 2005
Unidirectional whole body turning: a new lateralising sign in complex partial seizuresG Shukla, M Bhatia, M V Padma Srivastava, et al.
Journal of Ophthalmology|February 2, 2024
Long-Term Surgical Outcomes of Glaucoma Drainage Implants in Eyes with Preoperative Intraocular Pressure Less than 19 mmHgShahin Hallaj, Jae-Chiang Wong, Lauren E Hock, et al.
The Review of Scientific Instruments|July 10, 2021
Observations of visible argon line emissions and its spatial profile from Aditya-U tokamak plasmaK Shah, J Ghosh, G Shukla, et al.
Pageof 9